BioSpace News Archive

Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc. announced today interim clinical data from a Phase Ⅱ trial (TRUST) evaluating taletrectinib (AB-106)

Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”) and Intract Pharma (“Intract”) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intract’s Soteria® and Phloral® drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.

PDS Biotechnology Corporation today announced that its management will participate in the Benzinga Healthcare Small Cap Conference.

Acasti Pharma Inc. today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to currently marketed oral nimodipine capsules in 50 healthy subjects.

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium solution as part of its population health offering.

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.

TAE Life Sciences, a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy, announced the successful installation of its neutron beam system at Xiamen Humanity Hospital, the most advanced accelerator-based BNCT facility in Greater China, newly built in partnership with Neuboron Medical Group.

Nicox SA, an international ophthalmology company, reported the financial results for Nicox SA and its subsidiaries for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs.

Vifor Fresenius Medical Care Renal Pharma announced that Japan’s Ministry of Health and Labor Welfare has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment of patients with granulomatosis with polyangiitis and microscopic polyangiitis, the two main types of ANCA-associated vasculitis, a rare and severe autoimmune renal disease with high unmet medical need.